Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Wed, 06.08.2025
Evotec SE
Hamburg, Germany, 06 August 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.
The Company is going to hold a conference call to discuss the results as well as provide an u [ … ]
Wed, 30.07.2025
Evotec SE
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz
Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ advanced continuous manufacturing technology
[ … ]
Mon, 21.07.2025
Evotec SE
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec’s differentiated platforms
High-margin technology license revenues expected to have a stronger impact than anticipated
Significant cost optimization in excess of initial targets from Priority Reset [ … ]
Wed, 25.06.2025
Evotec SE
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK
The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr [ … ]
Tue, 03.06.2025
Evotec SE
All agenda items adopted
Under the topic “Pioneering Drug Discovery” CEO Dr Christian Wojczewski presented Evotec’s current situation and strategic outlook
46.45% of the registered share capital represented
Hamburg, Germany, 03 June 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that [ … ]
Wed, 07.05.2025
Evotec SE
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.
The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies.
[ … ]
Tue, 06.05.2025
Evotec SE
Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just – Evotec Biologics with continuing growth momentum
Strong progress in strategic protein degradation partnership with Bristol Myers Squibb
Strategy building on technology and science leadership: Focus on high-growth, high-value segme [ … ]
Tue, 29.04.2025
Evotec SE
Hamburg, Germany, 29 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call [ … ]
Thu, 24.04.2025
Evotec SE
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 24 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt [ … ]
Thu, 17.04.2025
Evotec SE
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth
Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence
Strong Q4 2024 revenue and EBITDA results in spite of ch [ … ]
